Bangalore: A combination five-in-one pill using three existing blood pressure drugs, a cholesterol-lowering statin and the popular pain reliever aspirin has shown promising results in reducing risks of cardiovascular disorders and stroke by about half, says a new study in this week’s issue of the medical journal ‘Lancet’.
In one of the largest such studies on 2,053 patients across 50 centres in India, the new pill made by Ahmedabad-based Cadila Pharmaceuticals Ltd, which also sponsored the study, showed the tablet was effective in healthy people and led to meaningful changes in heart risk factors.
Trial participants were in the age group 45-80 years without heart disease but had at least one risk factor for developing cardiovascular problems.
Medical professionals have long theorized on the benefits of a combination pill in cardiac disorders, but it wasn’t known if such a drug could be formulated and at the same time be effective.
But the new clinical trial shows that the pill is “non-inferior to its individual components in terms of blood pressure and heart rate lowering”.
“The efficacy of such a polypill in reducing cardiovascular events remains unclear, and will require further investigation in Phase III clinical trials,” the study reported.